Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost–benefit comparison of olmesartan- and candesartan-based regimens

References

• National Institute of Health and Clinical Evidence. Hypertension: Guidelines for management of hypertension in adults in primary care. London 2006. http://www.nice.org.uk/CG034
   Google Scholar
• Mansia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007;16:135-232
   PubMed Web of Science ®Google Scholar
• Department of Health. nGMS Quality and Outcomes Framework 2009-10. London, 2009
   Google Scholar
• Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38
   PubMed Web of Science ®Google Scholar
• NHS Business Services: Prescription Services. Drug Tariff March 2011
   Google Scholar
• NHS Business Services: Prescription Services. PCT data for BNF 2.5.5.2. October-December 2010. FoI request No: 513163
   Google Scholar
• Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundam Clin Pharmacol 2007;21:181-90
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252-9
   PubMed Web of Science ®Google Scholar
• Karlson BW, Zetterstrand S, Olofsson B, et al. A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension. Blood Press 2009;18:149-56
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604
   PubMed Web of Science ®Google Scholar
• MacGregor GA, Viskoper JR, Antonios TF, et al. Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. Hypertension 2000;36:454-60
   PubMed Web of Science ®Google Scholar
• Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010;32:1252-69
   PubMed Web of Science ®Google Scholar
• British Medical Association and Royal Pharmaceutical Society. British National Formulary March 2011 (BNF 61) London, 2011
   Google Scholar
• Anonymous. Hydrochlorothiazide and bendroflumethiazide in low doses – a comparative trial. Acta Pharmacol Toxicol (Copenh) 1984;54(Suppl 1):47-51
   PubMedGoogle Scholar
• National Statistics. Prescription cost analysis: England 2009. http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-england–2009
   Google Scholar
• ISD Scotland. Prescription Cost Analysis: Scotland 2009. http://www.isdscotland.org/isd/2241.html
   Google Scholar
• Welsh Assembly. Prescription Cost Analysis Wales 2009. http://www.wales.nhs.uk/sites3/page.cfm?orgid=428&pid=13533
   Google Scholar
• HSC Business Services Organisation: Prescription Cost Analysis. http://www.centralservicesagency.com/display/statistics
   Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002;288:2981-997
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
   PubMed Web of Science ®Google Scholar
• Staessen JA, Birkenhager WH. Evidence that new antihypertensives are superior to older drugs. Lancet 2005;366:869-71
   PubMed Web of Science ®Google Scholar
• Heran BS, Wong MM, Heran IK, et al. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2008; CD003822
   Web of Science ®Google Scholar